Insomnia
Insomnia, also known as sleeplessness, is a common sleep disorder characterized by difficulty falling asleep or staying asleep, resulting in poor-quality sleep, daytime sleepiness, low energy, irritability, and a depressed mood, potentially leading to impaired functioning and an increased risk of accidents. The condition can be short-term or long-term and significantly affects quality of life.
Health Outcomes
- Absence of Serious Adverse Events
- Altered Endocannabinoid System Function Due to Specific Strain
- Altered Sleep Architecture
- Altered Sleep Patterns
- Comparable Tolerability
- Extended Nighttime Activity Duration
- High Treatment Acceptability
- Improved Circadian-Metabolic Function
- Improved Daytime Alertness
- Improved Depressive Symptoms
- Improved Energy Levels
- Improved Enjoyment of Life
- Improved Fatigue Index
- Improved Feeling of Well-being
- Improved General Well-Being
- Improved Global Symptom
- Improved Health Perception
- Improved Insomnia
- Improved Menopause Symptom
- Improved Mental Health
- Improved Mental Well-Being
- Improved NREM Sleep Intensity
- Improved Neuroendocrine Stress Markers
- Improved Next Day Drowsiness
- Improved Parasympathetic Activity
- Improved Patient Satisfaction
- Improved Perceived Physical Health
- Improved Productive Performance
- Improved Recovery on Waking
- Improved Refreshment on Waking
- Improved Relaxation
- Improved Satisfaction
- Improved Secondary Symptoms
- Improved Self-Rated Vigor
- Improved Sleep
- Improved Sleep Disturbance
- Improved Sleep Duration
- Improved Sleep Efficacy
- Improved Sleep Efficiency
- Improved Sleep Intensity
- Improved Sleep Maintenance
- Improved Sleep Quality
- Improved Sleep Satisfaction
- Improved Sleep-Related Recovery in Participants with High Chronic Stress
- Improved Sleep-Related and Safety Behaviour Questionnaire Score
- Improved Somatic Symptoms
- Improved Stress Management
- Improved Sympathetic Tone
- Improved Symptom Score
- Improved Symptoms
- Improved Waking Quality
- Improved Well-Being
- Improved Work Capacity
- Improved Work Performance
- Increased 5-Hydroxytryptophan Levels
- Increased Cortisol Levels
- Increased EEG Delta Power in Subjects with Lower AIS Scores
- Increased Energy Levels
- Increased GABAergic Signaling
- Increased Irritability
- Increased Need for Repeated Dosing
- Increased Production of Beneficial Neurotransmitter GABA
- Increased Proportion of Healthy Days
- Increased Stress Biomarkers
- Increased Systemic GABA Levels
- Increased Time in Bed
- Increased Wakefulness
- Maintained N3 Sleep Quality
- No Change in Anxiety
- No Change in Negative Mood States
- No Clear Effect on Depression
- No Conclusive Efficacy
- Occurrence of Mild Adverse Events
- Reduced ADHD Symptoms
- Reduced Awake Time
- Reduced Daily Life Disturbance
- Reduced Daytime Drowsiness
- Reduced Digital Eye Strain Symptoms
- Reduced Discontinuation Rates
- Reduced Disturbed Sleep Night
- Reduced Fatigue
- Reduced Frequency of Disturbed Sleep
- Reduced Interference with Daily Life
- Reduced Mental Fatigue
- Reduced NREM Sleep Quality
- Reduced Nighttime Waking
- Reduced Non-Pain Symptoms
- Reduced Occurrence of Major Depressive Disorder
- Reduced Perceived Stress
- Reduced Physical Symptoms of Stress
- Reduced Sleep Disturbance Score
- Reduced Sleep Duration
- Reduced Sleeplessness
- Reduced Stress Hormone Levels
- Reduced Stress Indicators
- Reduced Stress Levels
- Reduced Stress-Induced Sleep Disruption
- Reduced Stress-Related Discomfort
- Reduced Symptom Severity
- Reduced Symptom Severity Scale Score
- Reduced Total Symptom Score
- Reduced Vigilance Behavior
- Reduced Wake After Sleep Onset
- Reduced Waking Frequency
- Safety Comparable to Control
- Symptom Alleviation
- Unchanged Salivary IgA Levels
- Unchanged Symptom Severity
- Well-Tolerated Supplementation